Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Vanguard S&P 500 ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Vanguard S&P 500 ETF trades at $715.59 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 298× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 4,722,271). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Vanguard S&P 500 ETF for 55 Days on average.
| IOVA | VOO | |
|---|---|---|
Market Cap | $6.04B | $1.80T |
Volume | 14,805,993 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $14.82 | $716.17 |
52-Week Low | $1.81 | $580.93 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VOO trades at $715.59 with a slight 0.16% daily gain, showing technical bullish momentum with strong moving average support. The ETF maintains its position as a core S&P 500 holding with upcoming dividend distribution. Recent news highlights its role in long-term wealth building and recession resilience, though short interest increased 46.9% in September according to Defense World data.
VOO offers diversified exposure to large-cap US equities with low expense ratio advantages. The main investment case centers on long-term market participation, though investors face S&P 500 valuation concerns and potential earnings growth slowdown from 35% to 15% in 2027 as noted by 24/7 Wall Street. Dividend yield remains modest compared to income-focused alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
